FEB 13, 2013
Bausch & Lomb's Victus femtosecond laser platform has received FDA clearance for use of the device to create penetrating arcuate incisions in the cornea for patients undergoing cataract surgery or other ophthalmic treatment in which such an incision is required.
The Victus platform received the CE mark in Europe in 2011 and FDA clearance in the U.S. in July 2012.
In the U.S., the system was previously approved to create corneal flaps during LASIK and anterior capsulotomy during cataract surgery. It has the same approvals in Europe as in the U.S., along with IntraCor, capsulotomy and lens fragmentation.
"With the additional FDA clearance in the U.S. for arcuate incisions, physicians can now perform multiple sight-enhancing procedures on patients using the Victus platform," said John Barr, executive vice president and president, Bausch & Lomb Global Surgical. "This clearance enhances our already comprehensive offering in cataract and refractive surgery and makes the Victus one of the most capable femtosecond lasers currently cleared for use in the U.S."